Slingshot members are tracking this event:
Celgene's Phase 3 REMARC Data for non-Hodgkin Lymphoma Expected Mid-Year
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jul 25, 2016
- What Can We Expect from Celgene's Phase 3 REMARC Trial Data for Non-Hodgkin Lymphoma? CELG Execute By: Aug 31, 2016
Related Keywords Lymphoma, Revlimid, Remarc Trial